Valuation: Larimar Therapeutics, Inc.

Market Cap 447M 391M 360M 333M 632M 42.61B 642M 4.31B 1.69B 20.99B 1.68B 1.64B 72.16B P/E 2026 *
-2.65x
P/E 2027 * -3.44x
Enterprise Value 270M 236M 218M 201M 382M 25.79B 389M 2.61B 1.02B 12.7B 1.02B 993M 43.67B EV / Sales 2026 *
-
EV / Sales 2027 * 4.19x
Free-Float
96.75%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Larimar Therapeutics, Inc.

1 day+3.63%
1 week+31.29%
Current month+40.33%
1 month+24.42%
3 months-11.75%
6 months+28.53%
Current year+12.34%
1 week 3.21
Extreme 3.21
4.32
1 month 2.92
Extreme 2.92
4.32
Current year 2.72
Extreme 2.715
6.42
1 year 2.72
Extreme 2.715
6.42
3 years 1.61
Extreme 1.61
13.68
5 years 1.53
Extreme 1.53
15.26
10 years 1.53
Extreme 1.53
25.87
Manager TitleAgeSince
Chief Executive Officer 67 2020-04-30
Director of Finance/CFO 67 2020-05-27
Chief Tech/Sci/R&D Officer 65 2023-07-16
Director TitleAgeSince
Director/Board Member 67 2019-12-31
Chairman 61 2020-05-27
Director/Board Member 58 2020-05-27
Date Insider Type Main position Quantity % Market Cap.
07-05Buy

Director

50,000 0.0584%
05-18Free

Director

55,150 0.0644%
05-18Free

Director

55,150 0.0644%
Change 5-day change 1-year change 3-year change Capi.($)
+3.63%+31.29%+22.99%+29.70% 447M
-4.14%-8.06%+57.35%+117.24% 54.63B
+1.84%-0.66%+75.79%+93.87% 54.88B
-2.24%+3.59%+19.60%+466.72% 25.06B
-1.60%-6.21%-19.69%-14.84% 23.14B
+2.43%+1.06%+47.70%-0.11% 19.88B
-3.19%0.00%+33.99%-26.87% 17.55B
-6.84%+2.18%+195.12%+357.18% 16.5B
-1.05%+1.16%+25.08%+196.28% 14.2B
+8.74%+3.51%+53.81% - 15.36B
Average -0.24%+2.42%+51.18%+135.46% 24.16B
Weighted average by Cap. -0.90%-1.41%+54.98%+137.57%

Financials

2026 *2027 *
Net sales - 57.06M 49.91M 46.04M 42.52M 80.68M 5.44B 82.04M 550M 216M 2.68B 214M 210M 9.22B
Net income -157M -138M -127M -117M -223M -15.02B -226M -1.52B -596M -7.4B -591M -578M -25.43B -157M -137M -126M -117M -221M -14.94B -225M -1.51B -593M -7.36B -588M -575M -25.3B
Net Debt -176M -154M -142M -131M -249M -16.82B -254M -1.7B -668M -8.29B -662M -648M -28.49B -208M -182M -168M -155M -294M -19.83B -299M -2B -787M -9.77B -781M -764M -33.58B
Logo Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The Company intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.
Employees
71
Date Price Change Volume
26-07-10 US$4.280 +3.63% 3,445,587
26-07-09 US$4.130 +14.40% 3,823,933
26-07-08 US$3.610 +5.87% 2,063,889
26-07-07 US$3.410 +3.65% 1,741,701
26-07-06 US$3.290 +0.92% 1,750,854
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
4.280USD
Average target price
14.40USD
Spread / Average Target
+236.45%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LRMR Stock